No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(-)-epicatechin |
Epicatechin |
- |
- |
- |
2件: 86, 113 |
2 |
(pyr1)apelin-13 |
- |
- |
- |
- |
1件: 86 |
3 |
11c acetate |
Acetate |
- |
- |
- |
1件: 86 |
4 |
11c-acetate |
Acetate |
- |
- |
- |
3件: 13, 86, 88 |
5 |
120 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
1件: 86 |
6 |
15 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
1件: 86 |
7 |
150mg cxa-10 |
- |
- |
- |
- |
1件: 86 |
8 |
2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-n-(methylsulfonyl)actamide |
- |
- |
- |
- |
1件: 86 |
9 |
20 mg sildenafil citrate by mouth |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
10 |
25% mtd sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
1件: 86 |
11 |
45 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
1件: 86 |
12 |
4au76 |
- |
- |
- |
- |
1件: 86 |
13 |
66215-101 |
- |
- |
- |
- |
1件: 86 |
14 |
6r-bh4 |
Sapropterin |
D08505 |
- |
- |
3件: 86, 124, 240 |
15 |
75mg cxa-10 |
- |
- |
- |
- |
1件: 86 |
16 |
90 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
1件: 86 |
17 |
[11c]-gsk2256098 500 mbq |
- |
- |
- |
- |
1件: 86 |
18 |
[18f] fes |
- |
- |
- |
- |
1件: 86 |
19 |
[18f]fluoro-2-deoxy-2-d-glucose |
D-glucose |
D00009 |
- |
- |
2件: 86, 88 |
20 |
Abi-009, nab-rapamycin, albumin-bound rapamycin |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
1件: 86 |
21 |
Access program - sildenafil citrate, viagra, revatio |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
22 |
Acetaminophen |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
11件: 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
23 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
24 |
Act-050089 |
- |
- |
- |
- |
1件: 86 |
25 |
Act-050089 (ro 61-0612) |
- |
- |
- |
- |
1件: 86 |
26 |
Act-064992 |
- |
- |
- |
- |
4件: 85, 86, 88, 210 |
27 |
Act-064992d |
- |
- |
- |
- |
1件: 86 |
28 |
Act-293987 |
- |
- |
- |
- |
2件: 51, 86 |
29 |
Act-293987 (ns-304) |
- |
- |
- |
- |
1件: 86 |
30 |
Act-385781a |
- |
- |
- |
- |
1件: 86 |
31 |
Act-385781a (actelion epoprostenol) |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
32 |
Adcirca |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
33 |
Adempas |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
4件: 51, 86, 225, 299 |
34 |
Adempas (riociguat, bay63-2521) |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
35 |
Adempas 0.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 299 |
36 |
Adempas 1.0 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 299 |
37 |
Adempas 1.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
38 |
Adempas 2.0 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 299 |
39 |
Adempas 2.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
40 |
Adempas® |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 88 |
41 |
Aerosolized iloprost |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
42 |
Air001 |
- |
- |
- |
- |
1件: 86 |
43 |
Air001 (sodium nitrite inhalation solution) |
Nitrite |
- |
- |
- |
1件: 86 |
44 |
Air001 inhalation solution |
- |
- |
- |
- |
1件: 86 |
45 |
Air001 inhalation solution (expansion arm) |
- |
- |
- |
- |
1件: 86 |
46 |
Albuterol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 12, 13, 86, 89, 113, 231, 256, 299 |
47 |
Albuterol first |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
48 |
Albuterol. |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
49 |
Allogeneic human cardiosphere-derived stem cells |
- |
- |
- |
- |
1件: 86 |
50 |
Ambrisentan |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 51, 84, 85, 86, 88, 211 |
51 |
Ambrisentan - high dose |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
52 |
Ambrisentan - low dose |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
53 |
Ambrisentan 5 mg film-coated tablets |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
54 |
Ambrisentan plus spironolactone |
Spironolactone |
D00443 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
1件: 86 |
55 |
Amn107 |
- |
- |
- |
- |
2件: 34, 86 |
56 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
57 |
Anastrozole |
Anastrozole |
D00960 |
1件: CYP19A1 |
3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis |
3件: 78, 86, 193 |
58 |
Angiotensin |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
7件: 17, 19, 46, 66, 86, 222, 224 |
59 |
Apabetalone |
Apabetalone |
D11131 |
- |
- |
1件: 86 |
60 |
Apd811 |
- |
- |
- |
- |
1件: 86 |
61 |
Apelin |
- |
- |
- |
- |
1件: 86 |
62 |
Ar392830 |
- |
- |
- |
- |
1件: 86 |
63 |
Aspirin |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
64 |
Assigned pulmonary hypertension medication |
- |
- |
- |
- |
1件: 86 |
65 |
Autologous epcs transfected |
- |
- |
- |
- |
1件: 86 |
66 |
Autologous epcs transfected with human enos |
- |
- |
- |
- |
1件: 86 |
67 |
Aviptadil |
Aviptadil |
- |
- |
- |
4件: 49, 51, 85, 86 |
68 |
Bardoxolone |
Bardoxolone |
D09584 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
69 |
Bardoxolone methyl |
Bardoxolone methyl |
D09585 |
- |
- |
7件: 66, 67, 84, 85, 86, 218, 222 |
70 |
Bardoxolone methyl capsules |
Bardoxolone methyl |
D09585 |
- |
- |
4件: 66, 67, 86, 222 |
71 |
Bay 63-2521 |
- |
- |
- |
- |
2件: 86, 88 |
72 |
Bay 63-2521 0.06 % |
- |
- |
- |
- |
1件: 86 |
73 |
Bay 63-2521 0.3 % |
- |
- |
- |
- |
1件: 86 |
74 |
Bay 63-2521 ir tablets 0.5 mg |
- |
- |
- |
- |
1件: 86 |
75 |
Bay 63-2521 ir tablets 1 mg |
- |
- |
- |
- |
1件: 86 |
76 |
Bay 63-2521 ir tablets 1.0 mg |
- |
- |
- |
- |
1件: 86 |
77 |
Bay 63-2521 ir tablets 1.5 mg |
- |
- |
- |
- |
1件: 86 |
78 |
Bay 63-2521 ir tablets 2.0 mg |
- |
- |
- |
- |
1件: 86 |
79 |
Bay 63-2521 ir tablets 2.5 mg |
- |
- |
- |
- |
1件: 86 |
80 |
Bay 63-2521 tablet |
- |
- |
- |
- |
1件: 86 |
81 |
Bay 63-2521 tablets 0.5 mg |
- |
- |
- |
- |
2件: 86, 88 |
82 |
Bay 63-2521 tablets 1 mg |
- |
- |
- |
- |
2件: 86, 88 |
83 |
Bay 63-2521 tablets 1.5 mg |
- |
- |
- |
- |
2件: 86, 88 |
84 |
Bay 63-2521 tablets 2 mg |
- |
- |
- |
- |
2件: 86, 88 |
85 |
Bay 63-2521 tablets 2.5 mg |
- |
- |
- |
- |
2件: 86, 88 |
86 |
Bay q 6256 |
- |
- |
- |
- |
1件: 86 |
87 |
Bay1237592 |
- |
- |
- |
- |
2件: 86, 88 |
88 |
Bay63-2521 |
- |
- |
- |
- |
3件: 51, 86, 299 |
89 |
Beetroot juice |
- |
- |
- |
- |
1件: 86 |
90 |
Benzbromaron |
Benzbromarone |
D01056 |
- |
- |
1件: 86 |
91 |
Benzbromaron al |
Benzbromarone |
D01056 |
- |
- |
1件: 86 |
92 |
Benzbromarone |
Benzbromarone |
D01056 |
- |
- |
1件: 86 |
93 |
Beraprost |
Beraprost |
D02720 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
94 |
Beraprost sodium |
Beraprost |
D02720 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
95 |
Beraprost sodium 314d modified release tablets |
Beraprost |
D02720 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
96 |
Beraprost sodium modified release |
Beraprost |
D02720 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
97 |
Bevacizumab |
Bevacizumab |
D06409 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
98 |
Bia 5-1058 |
- |
- |
- |
- |
1件: 86 |
99 |
Bia-5-1058 |
- |
- |
- |
- |
1件: 86 |
100 |
Biological dmards |
- |
- |
- |
- |
1件: 86 |
101 |
Bisoprolol |
Bisoprolol |
D00634, D02342 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 67, 86, 113 |
102 |
Blood test |
- |
- |
- |
- |
5件: 36, 86, 113, 162, 299 |
103 |
Bosentan |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 13, 41, 47, 51, 84, 85, 86, 88, 210 |
104 |
Bosentan administration |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
105 |
Bosentan and sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
106 |
Bosentan monohydrat |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
107 |
Bosentan monohydrate |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 84, 86, 88 |
108 |
Bosentan, ambrisentan |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
109 |
Bps-314d-mr |
- |
- |
- |
- |
1件: 86 |
110 |
Bps-mr |
- |
- |
- |
- |
1件: 86 |
111 |
Bsf 208075 |
- |
- |
- |
- |
1件: 86 |
112 |
C07ab07 |
- |
- |
- |
- |
1件: 86 |
113 |
C225 |
Cetuximab |
D03455 |
1件: EGFR |
45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
2件: 51, 86 |
114 |
Capsaicin |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
115 |
Captopril |
Captopril |
D00251 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
2件: 17, 86 |
116 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
117 |
Carbon monoxide |
Carbon monoxide |
D09706 |
- |
- |
3件: 85, 86, 298 |
118 |
Carvedilol |
Carvedilol |
D00255, D03415 |
5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 |
12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 6, 57, 86, 113 |
119 |
Cetuximab |
Cetuximab |
D03455 |
1件: EGFR |
45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
5件: 34, 51, 86, 89, 331 |
120 |
Chlorhexidine |
Chlorhexidine |
D00858, D01345, D03463, D07668 |
- |
- |
2件: 86, 299 |
121 |
Cialis |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 51, 86 |
122 |
Cialis 10 mg film-coated tablets |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 86, 113 |
123 |
Cialis 2.5 mg film-coated tablets |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 86, 113 |
124 |
Cialis 20 mg film-coated tablets |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 86, 113 |
125 |
Cialis 5 mg film-coated tablets |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 86, 113 |
126 |
Cicletanine |
Cicletanine |
D03487 |
- |
- |
1件: 86 |
127 |
Citrulline |
L-citrulline |
D07706 |
- |
- |
2件: 86, 113 |
128 |
Clopidogrel |
Clopidogrel |
D00769, D07729, D10823, D10824 |
1件: P2RY12 |
1件: Platelet activation |
2件: 49, 86 |
129 |
Coenzyme q-10 |
Ubidecarenone |
D01065 |
- |
- |
1件: 86 |
130 |
Coenzyme q-10 in normal control subjects |
Ubidecarenone |
D01065 |
- |
- |
1件: 86 |
131 |
Coenzyme q-10 in pulmonary hypertension subjects |
Ubidecarenone |
D01065 |
- |
- |
1件: 86 |
132 |
Commercial ventavis® (iloprost) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
133 |
Conivaptan |
Conivaptan |
D01236, D07748 |
2件: AVPR1A, AVPR2 |
5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption |
1件: 86 |
134 |
Current marketed flolan (epoprostenol sodium) |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
135 |
Cxa-10 |
- |
- |
- |
- |
2件: 86, 222 |
136 |
D-glucose |
D-glucose |
D00009 |
- |
- |
3件: 49, 86, 88 |
137 |
Dhea |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
3件: 49, 86, 96 |
138 |
Dhea tablet |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 86 |
139 |
Dichloroacetate |
Dichloroacetic acid |
- |
- |
- |
1件: 86 |
140 |
Dichloroacetate sodium |
Dichloroacetic acid |
- |
- |
- |
1件: 86 |
141 |
Diltiazem |
Diltiazem |
D00616, D03830, D07845 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 58, 86, 130 |
142 |
Diltiazem hydrochloride |
Diltiazem |
D00616, D03830, D07845 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
143 |
Dimethyl fumarate |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
3件: 13, 51, 86 |
144 |
Dimethyl fumarate (dmf) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
3件: 13, 51, 86 |
145 |
Diphenhydramine |
Diphenhydramine |
D00300, D00669, D02419, D03285, D03360, D03854 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
5件: 49, 51, 70, 86, 256 |
146 |
Efi/act-385781a |
- |
- |
- |
- |
1件: 86 |
147 |
Elafin |
Elafin |
- |
- |
- |
1件: 86 |
148 |
Endothelin receptor antagonist therapy |
- |
- |
- |
- |
1件: 86 |
149 |
Endothelin-3 |
- |
- |
- |
- |
1件: 86 |
150 |
Enos transfected epcs will be delivered via a pa line |
- |
- |
- |
- |
1件: 86 |
151 |
Epicatechin |
Epicatechin |
- |
- |
- |
2件: 86, 113 |
152 |
Epoprostenol |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
153 |
Epoprostenol for injection |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
154 |
Epoprostenol sodium |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
155 |
Epoprostenol-actelion |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
156 |
Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan) |
Macitentan, Sildenafil |
D02229, D08514, D10135 |
3件: EDNRA, EDNRB, PDE5A |
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
157 |
Erbitux |
Cetuximab |
D03455 |
1件: EGFR |
45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
2件: 51, 86 |
158 |
Esomeprazole |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
159 |
Eutonic treprostinil solution |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
160 |
Famotidine |
Famotidine |
D00318 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
3件: 6, 46, 86 |
161 |
Famotidine 20 mg |
Famotidine |
D00318 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
1件: 86 |
162 |
Fdc macitentan/tadalafil |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
163 |
Ferinject |
- |
- |
- |
- |
1件: 86 |
164 |
Ferinject or cosmofer |
- |
- |
- |
- |
1件: 86 |
165 |
Ferric carboxymaltose |
Ferric carboxymaltose |
D08920 |
- |
- |
4件: 86, 96, 97, 299 |
166 |
Ferricarboxymaltose |
- |
- |
- |
- |
1件: 86 |
167 |
Fk506 |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
2件: 86, 222 |
168 |
Fk506 level 2-3 ng/ml |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
169 |
Fk506 level 3-5 ng/ml |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
170 |
Fk506 level < 2 ng/ml |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
171 |
Flolan injection with currently marketed diluent |
- |
- |
- |
- |
1件: 86 |
172 |
Flolan injection with reformulated diluent |
- |
- |
- |
- |
1件: 86 |
173 |
Flolan tm and glycine diluent |
Glycine |
D00011 |
- |
- |
1件: 86 |
174 |
Flolan® |
- |
- |
- |
- |
1件: 86 |
175 |
Flolan™ and glycine diluent |
Glycine |
D00011 |
- |
- |
1件: 86 |
176 |
Fluoxetine |
Fluoxetine |
D00326, D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
4件: 13, 17, 78, 86 |
177 |
Fulvestrant |
Fulvestrant |
D01161 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 86 |
178 |
Gb002 |
- |
- |
- |
- |
1件: 86 |
179 |
Glivec |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 51, 86 |
180 |
Glivec 100 mg comprimidos recubiertos con película |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 34, 86 |
181 |
Glivec® |
- |
- |
- |
- |
1件: 86 |
182 |
Glivec® 100 mg filmtabletten |
- |
- |
- |
- |
1件: 86 |
183 |
Glycine |
Glycine |
D00011 |
- |
- |
4件: 35, 86, 226, 299 |
184 |
Gsk1325760 |
- |
- |
- |
- |
2件: 86, 88 |
185 |
Gsk1325760a |
- |
- |
- |
- |
1件: 86 |
186 |
Gsk2586881 |
- |
- |
- |
- |
1件: 86 |
187 |
Hgp1206 |
- |
- |
- |
- |
1件: 86 |
188 |
Hydroxyurea |
Hydroxyurea |
D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
189 |
Hypotonictreprostinil solution |
- |
- |
- |
- |
1件: 86 |
190 |
I.v. selexipag |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
191 |
Ifetroban |
Ifetroban |
D04500 |
1件: TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
3件: 51, 86, 113 |
192 |
Ilomedin 20 |
- |
- |
- |
- |
1件: 86 |
193 |
Ilomedin 20 [20 µg / ml] |
- |
- |
- |
- |
1件: 86 |
194 |
Iloprost |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
4件: 51, 84, 85, 86 |
195 |
Iloprost (5 µg) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
196 |
Iloprost (ventavis bayq6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
197 |
Iloprost (ventavis inhaled, bayq6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
198 |
Iloprost (ventavis, bayq 6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
199 |
Iloprost (ventavis, bayq6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
200 |
Iloprost (ventavis®) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
201 |
Iloprost inhalation solution (ventavis) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 85, 86 |
202 |
Iloprost pd-15 |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
203 |
Iloprost pd-6 |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
204 |
Iloprost,(ventavis, bayq6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
205 |
Imatinib |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
206 |
Imatinib mesilate |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 13, 86 |
207 |
Imatinib mesylate |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 13, 28, 34, 51, 86 |
208 |
Inhaled dry powder treprostinil (liq861) |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
209 |
Inhaled iloprost (ventavis, bayq6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
210 |
Inhaled nitric oxide |
Nitric oxide |
D00074 |
- |
- |
2件: 85, 86 |
211 |
Inhaled nitric oxide & inopulse delivery |
Nitric oxide |
D00074 |
- |
- |
1件: 86 |
212 |
Inhaled nitric oxide 75 mcg/kg ibw/hr |
Nitric oxide |
D00074 |
- |
- |
2件: 85, 86 |
213 |
Inhaled no with pulsed delivery |
- |
- |
- |
- |
1件: 86 |
214 |
Inhaled prostacyclin |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
215 |
Inhaled treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 84, 86 |
216 |
Intravenous administration of ferric carboxymaltose |
Ferric carboxymaltose |
D08920 |
- |
- |
1件: 86 |
217 |
Intravenous treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
218 |
Intravenous/subcutaneous treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
219 |
Ipratropium |
Ipratropium |
D02212 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 6, 86 |
220 |
Iron |
Iron |
- |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
221 |
Iron supplement |
Iron |
- |
- |
- |
1件: 86 |
222 |
Jtt-251 |
- |
- |
- |
- |
1件: 86 |
223 |
Kar5585 capsules |
- |
- |
- |
- |
1件: 86 |
224 |
L-citrulline |
L-citrulline |
D07706 |
- |
- |
2件: 86, 113 |
225 |
L-citrulline malate |
L-citrulline |
D07706 |
- |
- |
1件: 86 |
226 |
Levitra |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 13, 86 |
227 |
Lidocaine |
Lidocaine |
D00358, D02086, D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
8件: 6, 13, 46, 86, 168, 226, 231, 256 |
228 |
Liq861 inhaled treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
229 |
Lisuride |
Lisuride |
D01462, D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 86 |
230 |
Lloprost(ventavis,bayq6252, 10 µg/ml) |
- |
- |
- |
- |
1件: 86 |
231 |
Lloprost(ventavis,bayq6252, 20 µg/ml) |
- |
- |
- |
- |
1件: 86 |
232 |
Ly450190 |
- |
- |
- |
- |
1件: 86 |
233 |
Macitentan |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 51, 85, 86, 88, 210 |
234 |
Macitentan 10 mg |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 86, 88 |
235 |
Macitentan 10 mg tablet, once daily. |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
236 |
Macitentan group |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
237 |
Md-711 |
- |
- |
- |
- |
1件: 86 |
238 |
Medical air |
Medical air |
- |
- |
- |
3件: 85, 86, 193 |
239 |
Metformin |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
16件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
240 |
Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo |
- |
- |
- |
- |
1件: 86 |
241 |
Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb |
- |
- |
- |
- |
2件: 86, 88 |
242 |
Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth |
- |
- |
- |
- |
2件: 86, 88 |
243 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
244 |
Mk-5475 |
- |
- |
- |
- |
1件: 86 |
245 |
Mk-8892 |
- |
- |
- |
- |
1件: 86 |
246 |
Morphine |
Morphine |
D00842, D02271, D08233 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
4件: 36, 46, 70, 86 |
247 |
Morphine sulfate |
Morphine |
D00842, D02271, D08233 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
2件: 46, 86 |
248 |
Moxifloxacin |
Moxifloxacin |
D00874, D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
249 |
Moxifloxacin 400 mg |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 86 |
250 |
Multihance |
Gadobenic acid |
D04283, D08018 |
- |
- |
2件: 86, 88 |
251 |
Nebulized combination ipratropium bromide with salbutamol |
Ipratropium |
D02212 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 86 |
252 |
Nebulized ipratropium bromide |
Ipratropium |
D02212 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 86 |
253 |
New thermo stable formulation of epoprostenol sodium |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
254 |
Nicardipine |
Nicardipine |
D00617, D08270 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 70, 86 |
255 |
Nilotinib |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 6, 8, 34, 51, 86 |
256 |
Nitric oxide |
Nitric oxide |
D00074 |
- |
- |
7件: 46, 85, 86, 98, 251, 294, 299 |
257 |
Nitric oxide for inhalation |
Nitric oxide |
D00074 |
- |
- |
2件: 86, 299 |
258 |
Nitric oxide generated by the geno nitrosyl delivery system |
Nitric oxide |
D00074 |
- |
- |
1件: 86 |
259 |
Nitric oxide plus oxygen |
Nitric oxide |
D00074 |
- |
- |
1件: 86 |
260 |
Nitrite |
Nitrite |
- |
- |
- |
2件: 86, 299 |
261 |
Nitrosyl |
Nitric oxide |
D00074 |
- |
- |
1件: 86 |
262 |
Non-biologic dmards |
- |
- |
- |
- |
1件: 86 |
263 |
Ns-304 |
- |
- |
- |
- |
3件: 70, 86, 88 |
264 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
265 |
Nx1011 |
- |
- |
- |
- |
1件: 86 |
266 |
Observational study with patients treated with tracleer, ventavis, veletri, opsumit and/or uptravi |
- |
- |
- |
- |
1件: 86 |
267 |
Olaparib |
Olaparib |
D09730 |
3件: PARP1, PARP2, PARP3 |
4件: Apoptosis, Base excision repair, NF-kappa B signaling pathway, Necroptosis |
1件: 86 |
268 |
Opsumit |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 86, 88 |
269 |
Opsumit (macitentan) |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
270 |
Opsumit® |
- |
- |
- |
- |
3件: 86, 88, 210 |
271 |
Oral anticoagulant treatment |
- |
- |
- |
- |
1件: 86 |
272 |
Oral era |
- |
- |
- |
- |
1件: 86 |
273 |
Oral ifetroban |
Ifetroban |
D04500 |
1件: TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
2件: 51, 86 |
274 |
Oral pde5 inhibitors |
- |
- |
- |
- |
1件: 86 |
275 |
Oral selexipag (uptravi) |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
276 |
Oral sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
277 |
Oral treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 51, 86 |
278 |
Oral treprostinil (ut-15c) sustained release tablets |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
279 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
280 |
Oxygen supplementation |
Oxygen |
D00003 |
- |
- |
1件: 86 |
281 |
Pah medication |
- |
- |
- |
- |
1件: 86 |
282 |
Parenteral remodulin (treprostinil) injection |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
283 |
Pb1046 |
- |
- |
- |
- |
1件: 86 |
284 |
Pb1046 injection |
- |
- |
- |
- |
2件: 86, 113 |
285 |
Pb1046 subcutaneous injection |
- |
- |
- |
- |
1件: 86 |
286 |
Pf-00489791 |
- |
- |
- |
- |
1件: 86 |
287 |
Ph-combination therapy |
- |
- |
- |
- |
2件: 86, 88 |
288 |
Ph-monotherapy |
- |
- |
- |
- |
2件: 86, 88 |
289 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
290 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
291 |
Plx-pad |
- |
- |
- |
- |
1件: 86 |
292 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
293 |
Prostacyclin |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
294 |
Puri-nethol |
Mercaptopurine |
D00161, D04931 |
1件: HPRT1 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 86 |
295 |
Qcc374 |
- |
- |
- |
- |
1件: 86 |
296 |
Qcc374 0.015 mg |
- |
- |
- |
- |
1件: 86 |
297 |
Qcc374 0.06 mg |
- |
- |
- |
- |
1件: 86 |
298 |
Qti571 |
- |
- |
- |
- |
1件: 86 |
299 |
Qutenza |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 86 |
300 |
Qutenza (8% capsaicin) |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 86 |
301 |
Ralinepag |
Ralinepag |
D10725 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
302 |
Ranolazine |
Ranolazine |
D05700, D05701 |
- |
- |
6件: 2, 58, 86, 113, 114, 130 |
303 |
Rapamycin |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
16件: 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 158, 256, 278, 279 |
304 |
Rapid dose titration group of subcutaneous treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
305 |
Recombinant human angiotensin-converting enzyme 2 (ace2), apn01 |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
306 |
Remodulin |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
307 |
Remodulin (treprostinil sodium) |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
308 |
Remodulin® (treprostinil) 1 mg/ml solution for infusion |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
309 |
Remodulin® (treprostinil) 10 mg/ml solution for infusion |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
310 |
Remodulin® (treprostinil) 2.5 mg/ml solution for infusion |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
311 |
Remodulin® (treprostinil) 5 mg/ml solution for infusion |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
312 |
Revatio |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 85, 86 |
313 |
Revatio inyectable |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
314 |
Revatio oral |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
315 |
Revatio ® 20 mg film-coated tablets |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
316 |
Revatio® |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
317 |
Riciguat group |
- |
- |
- |
- |
1件: 86 |
318 |
Rifampin |
Rifampicin |
D00211 |
- |
- |
5件: 6, 13, 84, 86, 299 |
319 |
Riociguat |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
6件: 51, 84, 86, 88, 225, 299 |
320 |
Riociguat (adempas, bay63-2521) |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
3件: 51, 86, 88 |
321 |
Riociguat (bay63-2521) |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
322 |
Riociguat granules 0.3% for oral application |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
323 |
Riociguat oral product |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
324 |
Riociguat pill |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 86 |
325 |
Ritonavir |
Ritonavir |
D00427 |
- |
- |
4件: 2, 86, 130, 265 |
326 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
327 |
Ro 47-0203 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 88 |
328 |
Ro 47-0203 / act-050088 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
329 |
Ro-47-0203 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
330 |
Ro-47-0203/029 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
331 |
Ro47-0203 |
- |
- |
- |
- |
1件: 86 |
332 |
Ro47-0203 / act-050088 |
- |
- |
- |
- |
2件: 51, 86 |
333 |
Roactemra |
- |
- |
- |
- |
5件: 41, 46, 51, 86, 107 |
334 |
Rvg 33865 |
- |
- |
- |
- |
1件: 86 |
335 |
Rvt-1201 |
- |
- |
- |
- |
1件: 86 |
336 |
Salbutamol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 3, 11, 49, 85, 86, 228, 256, 299 |
337 |
Saline |
Sodium chloride |
D02056 |
- |
- |
10件: 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
338 |
Sapropterin |
Sapropterin |
D08505 |
- |
- |
3件: 86, 124, 240 |
339 |
Sapropterin dihydrochloride (6r-bh4) |
Sapropterin |
D08505 |
- |
- |
1件: 86 |
340 |
Saquinavir |
Saquinavir |
D00429, D01160 |
- |
- |
2件: 86, 265 |
341 |
Saquinavir and ritonavir |
Saquinavir |
D00429, D01160 |
- |
- |
1件: 86 |
342 |
Selexipag |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 70, 84, 86, 88 |
343 |
Selexipag (uptravi) |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
344 |
Selonsertib |
Selonsertib |
D10988 |
1件: MAP3K5 |
12件: Amyotrophic lateral sclerosis (ALS), Apoptosis, Fluid shear stress and atherosclerosis, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, TNF signaling pathway, Thermogenesis, Tight junction |
1件: 86 |
345 |
Serine |
Serine |
D00016 |
- |
- |
3件: 2, 6, 86 |
346 |
Sham o2 (medical air) |
Medical air |
- |
- |
- |
1件: 86 |
347 |
Sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
15件: 6, 46, 50, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
348 |
Sildenafil (as citrate) |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
349 |
Sildenafil (revatio) |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
350 |
Sildenafil (revatio) 20 mg tid |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
351 |
Sildenafil 20mg |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 51, 86 |
352 |
Sildenafil 20mg and bosentan 62.5mg |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 51, 86 |
353 |
Sildenafil citrate |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 225 |
354 |
Sildenafil citrate (uk-92,480) |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
355 |
Sildenafil singly or in association with bosentan |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
356 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
357 |
Sitaxentan |
Sitaxentan |
D07171 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
358 |
Sitaxentan sodium |
Sitaxentan |
D07171 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
359 |
Sitaxsentan |
Sitaxentan |
D07171 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
360 |
Sitaxsentan alone |
Sitaxentan |
D07171 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
361 |
Sitaxsentan and sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
362 |
Sitaxsentan sodium |
Sitaxentan |
D07171 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
363 |
Slow dose titration group of subcutaneous treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
364 |
Sodium nitrite |
Nitrite |
- |
- |
- |
2件: 86, 299 |
365 |
Sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
1件: 86 |
366 |
Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
367 |
Sorafenib |
Sorafenib |
D06272, D08524 |
8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET |
83件: Acute myeloid leukemia, Alcoholism, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway |
2件: 34, 86 |
368 |
Sotatercept |
Sotatercept |
D09670 |
1件: ACVR2A |
4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway |
2件: 86, 284 |
369 |
Spironolactone |
Spironolactone |
D00443 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
6件: 58, 67, 86, 113, 218, 225 |
370 |
Spironolactone and conivaptan |
Spironolactone |
D00443 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
1件: 86 |
371 |
Spironolactone captopril carvedilol |
Spironolactone |
D00443 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
1件: 86 |
372 |
Sti571 |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 51, 86 |
373 |
Subcutaneous and intravenous prostacyclin |
Epoprostenol |
D00106, D01337 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
374 |
Subcutaneous treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
375 |
Sugar pill |
- |
- |
- |
- |
7件: 6, 49, 67, 70, 86, 206, 226 |
376 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
377 |
Tadalafil |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
6件: 6, 51, 75, 84, 86, 113 |
378 |
Tadalafil 20 mg film-coated tablets |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
379 |
Tadalafil 40 mg |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
380 |
Tadalafil and ambrisentan upfront combination therapy |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 51, 86 |
381 |
Tadalafil oral suspension |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
382 |
Tadalafil, placebo |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
383 |
Tadalafil- tablet or oral suspension |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
384 |
Tamoxifen |
Tamoxifen |
D00966, D08559 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 2, 86, 113, 227 |
385 |
Tasigna |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 34, 86 |
386 |
Tasigna® |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 86 |
387 |
Tegaderm |
- |
- |
- |
- |
1件: 86 |
388 |
Terguride |
Terguride |
D01348 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
2件: 51, 86 |
389 |
Terguride 0.5 mg tablet |
Terguride |
D01348 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 86 |
390 |
Tezosentan |
Tezosentan |
- |
- |
- |
1件: 86 |
391 |
The pops study is collecting pk data on children prescribed the following drugs of interest per standard of care: |
- |
- |
- |
- |
1件: 86 |
392 |
Thelin |
Sitaxentan |
D07171 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 86 |
393 |
Threonine |
L-threonine |
D00041 |
- |
- |
3件: 86, 96, 97 |
394 |
Thrombin |
Thrombin |
D00090 |
- |
- |
2件: 86, 88 |
395 |
Tocilizumab |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
396 |
Traclear |
- |
- |
- |
- |
1件: 86 |
397 |
Tracleer |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 13, 51, 84, 85, 86, 88, 210, 211 |
398 |
Tracleer® |
- |
- |
- |
- |
1件: 86 |
399 |
Transdihydrolisuride |
- |
- |
- |
- |
2件: 51, 86 |
400 |
Treprostin |
- |
- |
- |
- |
1件: 86 |
401 |
Treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 84, 85, 86, 88 |
402 |
Treprostinil diethanolamine |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 51, 86 |
403 |
Treprostinil diolamine |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
404 |
Treprostinil inhalation powder |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
405 |
Treprostinil inhalations |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
406 |
Treprostinil injectable product |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
407 |
Treprostinil sodium |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 86, 88 |
408 |
Treprostinil sodium solution for inhalation |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
409 |
Treprostinil sodium, ut-15 |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
410 |
Treprostinil, ut-15, lrx-15, 15au81, bw a15au, u-62, 840 |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
411 |
Trimetazidine |
Trimetazidine |
D01606, D08642 |
- |
- |
2件: 58, 86 |
412 |
Trk-100stp |
- |
- |
- |
- |
1件: 86 |
413 |
Tyrosine |
Tyrosine |
D00022 |
- |
- |
3件: 6, 86, 111 |
414 |
Tyvaso inhalation solution |
- |
- |
- |
- |
1件: 86 |
415 |
Ubenimex |
Ubenimex |
D00087 |
1件: ANPEP |
4件: Glutathione metabolism, Hematopoietic cell lineage, Metabolic pathways, Renin-angiotensin system |
1件: 86 |
416 |
Udenafil |
Udenafil |
D10027 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 86 |
417 |
Uk-92,480 |
- |
- |
- |
- |
1件: 86 |
418 |
Uptravi |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
419 |
Ut-15c |
- |
- |
- |
- |
1件: 86 |
420 |
Ut-15c (treprostinil diethanolamine) |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
421 |
Ut-15c 0.25 mg |
- |
- |
- |
- |
1件: 86 |
422 |
Ut-15c 1 mg |
- |
- |
- |
- |
1件: 86 |
423 |
Ut-15c 5 mg |
- |
- |
- |
- |
1件: 86 |
424 |
Ut-15c sr |
- |
- |
- |
- |
2件: 51, 86 |
425 |
Ut-15c sr (treprostinil diethanolamine) |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
426 |
Vardenafil |
Vardenafil |
D02731, D03260, D08668 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
3件: 13, 86, 299 |
427 |
Ventavis |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
428 |
Ventavis (iloprost, bayq6256) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
429 |
Ventavis 10 |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
430 |
Ventavis(iloprost) |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 86 |
431 |
Viagra |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
3件: 86, 96, 225 |
432 |
Volibris |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 51, 86, 88 |
433 |
Zamicastat |
Zamicastat |
- |
- |
- |
1件: 86 |